ABT-199 Selectively Kills BCL-2-Dependent Tumor Cells While Sparing Platelets. A) Navitoclax (ABT-263) binds to both BCL-2 and BCL-XL. Platelets are dependent on the anti-apoptotic activity of BCL-XL for survival. Consequently, thrombocytopenia is a dose-limiting adverse effect of treatment with navitoclax. B) ABT-199 is specific for BCL-2 and induces selective death of BCL-2-dependent tumor cells while sparing platelets.Reprinted from Cancer Cell, 23, Davids MS and Letai A, Taking Dead Aim at BCL-2, page 140, 2013, with permission from Elsevier. Figure created by Richard Oakley.

ABT-199 Selectively Kills BCL-2-Dependent Tumor Cells While Sparing Platelets. A) Navitoclax (ABT-263) binds to both BCL-2 and BCL-XL. Platelets are dependent on the anti-apoptotic activity of BCL-XL for survival. Consequently, thrombocytopenia is a dose-limiting adverse effect of treatment with navitoclax. B) ABT-199 is specific for BCL-2 and induces selective death of BCL-2-dependent tumor cells while sparing platelets.Reprinted from Cancer Cell, 23, Davids MS and Letai A, Taking Dead Aim at BCL-2, page 140, 2013, with permission from Elsevier. Figure created by Richard Oakley.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal